Lipocine Announces Financial and Operational Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 7:42AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well as recent operational highlights.
LPCN: 4.95 (+0.35)
Lipocine beats by $0.23
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:19AM CST
LPCN: 4.95 (+0.35)
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TSCO: 73.95 (+0.06), SCSS: 26.66 (-0.33), XPLR: 5.73 (-0.57), LAKE: 11.39 (-0.85), LPCN: 4.95 (+0.35), LAWS: 22.93 (+1.14), VICR: 12.68 (-0.38), EGHT: 7.92 (-0.04), INFN: 13.84 (-0.58)
Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111
GlobeNewswire - Mon Oct 13, 6:09AM CDT
Candidate For Once Daily Dosing
LPCN: 4.95 (+0.35)
IPOs and Transactions Week in Review: September 29 - October 3
PR Newswire - Mon Oct 06, 1:25PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
RCAP: 11.35 (-0.24), CPTA: 18.17 (+0.24), PTN: 0.75 (-0.02), LPCN: 4.95 (+0.35), XGTI: 1.40 (-0.02), ENRJ: 4.10 (unch), SINO: 1.81 (unch)
SOXX, XONE, LPCN, Added To Naked Short Lists Today
M2 - Mon Oct 06, 9:30AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. iShares PHLX SOX Semiconductor Sector Index Fund (NASDAQ:SOXX), (NASDAQ:XONE), (NASDAQ:LPCN). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
XONE: 19.80 (-0.24), LPCN: 4.95 (+0.35), SOXX: 87.11 (+0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Sep 25, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OBCI: 3.40 (-0.13), LYTS: 7.08 (-0.27), ALCS: 0.30 (+0.01), ENVI: 1.60 (-0.05), JACQ: 11.00 (unch), LPCN: 4.95 (+0.35), FNJN: 2.68 (-0.27), RITT: 1.08 (-0.05), LAND: 10.80 (-0.07), ACOR: 33.73 (-1.17), FORD: 1.18 (unch)
Why Lipocine (LPCN) Stock Is Surging in Morning Trading Today
at The Street - Wed Sep 24, 8:50AM CDT
Shares of Lipocine (LPCN) soared in morning trading Wednesday after the pharmaceutical company announced positive results from its Phase 3 trial of its oral treatment LPCN 1021 for low testosterone.
LPCN: 4.95 (+0.35)
Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy
GlobeNewswire - Wed Sep 24, 7:30AM CDT
-- Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects
LPCN: 4.95 (+0.35)
Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021
GlobeNewswire - Tue Sep 23, 3:00PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast tomorrow, September 24, 2014 at 8:45 a.m. Eastern time to discuss top-line results from its Study of Oral Androgen Replacement ("SOAR"
LPCN: 4.95 (+0.35)